UnknownPhase 1

The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II

25 participantsStarted 2019-05

Plain-language summary

The study is an initial non-blinded, non-placebo controlled trial to determine the efficacy of L-glutamine in lowering blood sugar in patients with diabetes mellitus type II without sickle cell anemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of diabetes mellitus type II * Patient of Straub Medical Center, Internal Medicine Clinic Exclusion Criteria: * Renal and liver impairment ( GFR less than 40) * Transaminitis (elevation of AST of ALT more than 2 fold) * Patient with sickle cell anemia

What they're measuring

Change in fasting glucose

Timeframe: 3 months and 6 months

Change in hemoglobin A1c

Timeframe: 3 months and 6 months

Trial details

NCT IDNCT03947879

SponsorHawaii Pacific Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-05

Contact for this trial

Charles Zerez, MD, PhD

808-522-4000 czerez@straub.net

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials